Posted Two Blokes
byFirst results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu
Source: Two Blokes Trading
Posted Two Blokes
byFirst results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu
Source: Two Blokes Trading
Posted Two Blokes
byLargest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted
Source: Two Blokes Trading
Posted Two Blokes
byRivian (RIVN 4.42%) is expected to report earnings on May 6. So far this year, shares of the EV maker have bee
Source: Two Blokes Trading
Posted Two Blokes
byThere's no question that 2025 has been a rough year for AI stocks thus far.
Source: Two Blokes Trading
Posted Two Blokes
byAnxious investors who picked April to go on a long internet-free vacation couldn't have planned it better. Ear
Source: Two Blokes Trading
Posted Two Blokes
byMany investors are withdrawing their money from the stock market right now, but those focused on the long term
Source: Two Blokes Trading
Posted Two Blokes
byThe stock market has entered a new period of increased uncertainty and volatility following the Trump Administ
Source: Two Blokes Trading
Posted Two Blokes
byExxonMobil (XOM -0.03%) believes that carbon capture and sequestration (CCS) represents a massive opportunity
Source: Two Blokes Trading
Posted Two Blokes
byNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST tria
Source: Two Blokes Trading
Posted Two Blokes
byPhase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than
Source: Two Blokes Trading
Posted Two Blokes
byPhase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than
Source: Two Blokes Trading